Publication
Natural compounds: co-delivery strategies with chemotherapeutic agents or nucleic acids using lipid-based nanocarriers
| dc.contributor.author | Teixeira, Patrícia V. | |
| dc.contributor.author | Fernandes, Eduarda | |
| dc.contributor.author | Soares, Telma B. | |
| dc.contributor.author | Adega, Filomena | |
| dc.contributor.author | Lopes, Carla Martins | |
| dc.contributor.author | Lúcio, Marlene | |
| dc.date.accessioned | 2024-01-30T12:53:28Z | |
| dc.date.available | 2024-01-30T12:53:28Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Cancer is one of the leading causes of death, and latest predictions indicate that cancer- related deaths will increase over the next few decades. Despite significant advances in conventional therapies, treatments remain far from ideal due to limitations such as lack of selectivity, non-specific distribution, and multidrug resistance. Current research is focusing on the development of several strategies to improve the efficiency of chemotherapeutic agents and, as a result, overcome the challenges associated with conventional therapies. In this regard, combined therapy with natural compounds and other therapeutic agents, such as chemotherapeutics or nucleic acids, has recently emerged as a new strategy for tackling the drawbacks of conventional therapies. Taking this strategy into consideration, the co-delivery of the above-mentioned agents in lipid-based nanocarriers provides some advantages by improving the potential of the therapeutic agents carried. In this review, we present an analysis of the synergistic anticancer outcomes resulting from the combination of natural compounds and chemotherapeutics or nucleic acids. We also emphasize the importance of these co-delivery strategies when reducing multidrug resistance and adverse toxic effects. Furthermore, the review delves into the challenges and opportunities surrounding the application of these co-delivery strategies towards tangible clinical translation for cancer treatment. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Teixeira, P.V.; Fernandes, E.; Soares, T.B.; Adega, F.; Lopes, C.M.; Lúcio, M. Natural compounds: co-delivery strategies with chemotherapeutic agents or nucleic acids using lipid-based nanocarriers. Pharmaceutics 2023, 15, 1317. https://doi.org/10.3390/ pharmaceutics15041317 | pt_PT |
| dc.identifier.doi | 10.3390/pharmaceutics15041317 | pt_PT |
| dc.identifier.eissn | 1999-4923 | |
| dc.identifier.uri | http://hdl.handle.net/10284/12623 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | MDPI | pt_PT |
| dc.subject | Cancer | pt_PT |
| dc.subject | Conventional therapy | pt_PT |
| dc.subject | Combined therapy | pt_PT |
| dc.subject | Lipid-based nanocarriers | pt_PT |
| dc.subject | Natural compounds | pt_PT |
| dc.title | Natural compounds: co-delivery strategies with chemotherapeutic agents or nucleic acids using lipid-based nanocarriers | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 4 | pt_PT |
| oaire.citation.startPage | 1317 | pt_PT |
| oaire.citation.title | Pharmaceutics | pt_PT |
| oaire.citation.volume | 15 | pt_PT |
| person.familyName | Lopes | |
| person.givenName | Carla | |
| person.identifier.ciencia-id | 901D-160C-633E | |
| person.identifier.orcid | 0000-0001-5080-032X | |
| person.identifier.rid | M-4689-2016 | |
| person.identifier.scopus-author-id | 26649517700 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | d2a48cfe-9258-4916-99be-bbcb710f6605 | |
| relation.isAuthorOfPublication.latestForDiscovery | d2a48cfe-9258-4916-99be-bbcb710f6605 |